ImmunityBio (IBRX) is trading higher after disclosing on April 6, 2026 that it submitted a comprehensive response to the FDA Office of Prescription Drug Promotion regarding issues raised in the agency’s March 13, 2026 warning letter tied to ANKTIVA promotional communications. The company said it removed the identified podcast from its website and requested its removal from third-party hosting platforms, and stated the television advertisement cited by the FDA was never broadcast or disseminated.

The FDA letter alleged the TV ad and podcast were false or misleading and could create the impression ANKTIVA can cure or prevent cancers beyond its approved indication, raising regulatory and litigation overhang after the stock’s sharp March 2026 decline. Today’s disclosure is being treated as a de-risking step because it frames the company’s remediation actions and signals an active engagement path with regulators rather than escalation.

Key swing factors include whether the FDA deems the corrective actions sufficient, whether any additional communications are flagged, and whether ImmunityBio’s tightened promotional controls reduce the risk of future enforcement actions. Separately, traders will continue to focus on ANKTIVA commercial execution and any regulatory progress on supplemental filings or new indications, as those are the longer-term drivers that can outweigh short-term compliance headlines.